Acorah Software Products - Accounts Production 19.3.550 false true 31 July 2024 1 August 2023 false 1 August 2024 31 July 2025 31 July 2025 11465538 Mr Damion Carruel iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 11465538 2024-07-31 11465538 2025-07-31 11465538 2024-08-01 2025-07-31 11465538 frs-core:CurrentFinancialInstruments 2025-07-31 11465538 frs-core:Non-currentFinancialInstruments 2025-07-31 11465538 frs-core:ShareCapital 2025-07-31 11465538 frs-core:RetainedEarningsAccumulatedLosses 2025-07-31 11465538 frs-bus:PrivateLimitedCompanyLtd 2024-08-01 2025-07-31 11465538 frs-bus:FilletedAccounts 2024-08-01 2025-07-31 11465538 frs-bus:SmallEntities 2024-08-01 2025-07-31 11465538 frs-bus:AuditExempt-NoAccountantsReport 2024-08-01 2025-07-31 11465538 frs-bus:SmallCompaniesRegimeForAccounts 2024-08-01 2025-07-31 11465538 frs-bus:Director1 2024-08-01 2025-07-31 11465538 frs-countries:EnglandWales 2024-08-01 2025-07-31 11465538 2023-07-31 11465538 2024-07-31 11465538 2023-08-01 2024-07-31 11465538 frs-core:CurrentFinancialInstruments 2024-07-31 11465538 frs-core:Non-currentFinancialInstruments 2024-07-31 11465538 frs-core:ShareCapital 2024-07-31 11465538 frs-core:RetainedEarningsAccumulatedLosses 2024-07-31
Registered number: 11465538
Tanit Therapeutics Limited
Unaudited Financial Statements
For The Year Ended 31 July 2025
Contents
Page
Balance Sheet 1
Notes to the Financial Statements 2
Page 1
Balance Sheet
Registered number: 11465538
2025 2024
Notes £ £ £ £
CURRENT ASSETS
Debtors 4 488 498
Cash at bank and in hand 2 1
490 499
Creditors: Amounts Falling Due Within One Year 5 (14,004 ) (13,103 )
NET CURRENT ASSETS (LIABILITIES) (13,514 ) (12,604 )
TOTAL ASSETS LESS CURRENT LIABILITIES (13,514 ) (12,604 )
Creditors: Amounts Falling Due After More Than One Year 6 (31,818 ) (32,193 )
NET LIABILITIES (45,332 ) (44,797 )
CAPITAL AND RESERVES
Called up share capital 7 10 10
Profit and Loss Account (45,342 ) (44,807 )
SHAREHOLDERS' FUNDS (45,332) (44,797)
For the year ending 31 July 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Mr Damion Carruel
Director
22/07/2026
The notes on page 2 form part of these financial statements.
Page 1
Page 2
Notes to the Financial Statements
1. General Information
Tanit Therapeutics Limited is a private company, limited by shares, incorporated in England & Wales, registered number 11465538 . The registered office is 127 Daneland, Barnet, Hertfordshire, EN4 8QB.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements are prepared under the historical cost convention and in accordance with the FRS 102 Section 1A Small Entities - The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
3. Average Number of Employees
Average number of employees, including directors, during the year was: NIL (2024: NIL)
- -
4. Debtors
2025 2024
£ £
Due within one year
Trade debtors 488 488
Called up share capital not paid - 10
488 498
5. Creditors: Amounts Falling Due Within One Year
2025 2024
£ £
Accruals and deferred income 180 180
Director's loan account 13,824 12,923
14,004 13,103
6. Creditors: Amounts Falling Due After More Than One Year
2025 2024
£ £
Bank loans 31,818 32,193
7. Share Capital
2025 2024
£ £
Called Up Share Capital not Paid - 10
Called Up Share Capital has been paid up 10 -
Amount of Allotted, Called Up Share Capital 10 10
Page 2